LianBio to Participate in June Investor Events
LianBio (Nasdaq: LIAN) announced participation in upcoming investor conferences, including the Jefferies Healthcare Conference on June 10, 2022, and the Goldman Sachs Healthcare Conference on June 15, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LianBio (Nasdaq: LIAN) announced participation in upcoming investor conferences, including the Jefferies Healthcare Conference on June 10, 2022, and the Goldman Sachs Healthcare Conference on June 15, 2022. Both events will feature live audio webcasts accessible via the company's website. LianBio focuses on delivering innovative medicines to patients in China and other major Asian markets, advancing a diversified portfolio of product candidates across various therapeutic areas such as cardiovascular, oncology, and more.
Details
News Market Reaction – LIAN
The recorded move for LIAN in the trading session of this news was +1.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:
- Jefferies Healthcare Conference – June 10, 2022, at 11:00 am ET
- Goldman Sachs Healthcare Conference – June 15, 2022, at 2:40 pm PT
Live audio webcasts of the presentations will be accessible from the Investors section of LianBio’s website at https://investors.lianbio.com/ with replays available following the live events.
About LianBio
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit www.lianbio.com.
For investor inquiries, please contact:
Elizabeth Anderson, VP Communications and Investor Relations
E: elizabeth.anderson@lianbio.com
T: +1 646 655 8390
For media inquiries, please contact:
Katherine Smith, CanaleComm
E: katherine.smith@canalecomm.com
T: +1 619 849 5378
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.